VenBio raises $550 million in venture capital

By The Science Advisory Board staff writers

June 3, 2021 -- Life science venture capital firm VenBio announced it closed its fourth life sciences venture capital fund ("VenBio Fund IV") on approximately $550 million in capital commitments.

The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds, according to the company.

VenBio said it will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals for unmet medical needs. Since 2011, VenBio reports it has raised nearly $1.5 billion in capital commitments.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.